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Abstract
Estrogen and its receptors are implicated in the promotion and prevention of various cancers.
While the uterine cervix is highly responsive to estrogen, the role of estrogen in cervical cancer,
which is strongly associated with human papillomavirus (HPV) infections, is poorly understood.
Recent studies in HPV transgenic mouse models provide evidence that estrogen and its nuclear
receptor promote cervical cancer in combination with HPV oncogenes. While epidemiological
studies further support this hypothesis, there is little experimental data assessing the hormonal
responsiveness of human cervical cancers. If these cancers are dependent upon estrogen, then
drugs targeting estrogen and its receptors may be effective in treating and/or preventing cervical
cancer, the second leading cause of death by cancer amongst women worldwide.
Estrogen and cancer
Estrogen, through its nuclear receptors ERα and ERβ, and membrane receptor GPR30,
influences physiological processes in various tissues/systems including but not limited to the
female reproductive tract, breast, colon, brain, bone, cardiovascular and immune systems
(Figure 1a). Not surprisingly, estrogen is implicated in various human diseases including
cancer (e.g. breast, endometrium, and colon) wherein it can either promote or suppress
tumor development [1]. The uterine cervix is a part of the female reproductive tract that is
highly responsive to estrogen. During the menstrual cycle, cervical epithelial cells
proliferate and differentiate as estrogen levels increase, resulting in hyperplastic epithelium
without pathological changes. Estrogen and ERα, the major ER expressed in the cervix, are
necessary for this dynamic change in cervical epithelium. In this article we discuss
laboratory and epidemiological studies that provide insight into the roles of estrogen and its
receptor ERα in cervical cancer.
Cervical cancer
Cervical cancer is the second most frequent cancer and the second leading cause of cancer
death in women worldwide, with approximately 470,000 new cases and 233,000 deaths per
year [2]. The high mortality rate is largely due to the lack of effective therapies for
eliminating disease in women with high-grade cervical cancer and the lack of response to
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chemotherapy of inoperable disease. A major causal factor for cervical cancer is the high-
risk human papillomaviruses (HPVs), which are also associated with other anogenital
cancers as well as a small fraction of head & neck cancer (Box 1) [3]. Over 99% of human
cervical cancers are positive for these sexually transmitted HPVs [4]. Currently available
prophylactic vaccines that inhibit infection by a subset of high-risk HPVs hold promise for
reducing cervical cancer incidence in future generations of women [5]. These vaccines,
however, do not protect women who are already infected or afflicted by the cancer. The fact
that E6 and E7 are always expressed in HPV+ cervical cancer has led to great efforts in
developing therapeutic vaccines against these viral antigens. Although such therapeutic
vaccines induce viral antigen-specific cytotoxic T cells in human, they have largely proven
ineffective in treating HPV-induced cervical neoplasia in women [5].
Box 1
HPV and cancer
HPV is one of the most common sexually transmitted pathogen. It is estimated that ~75%
of sexually active individuals are infected by this virus. Over 100 different types of HPV
are identified and classified in two groups depending on their tissue tropism [62,63].
Cutaneous types (e.g. HPV-5 & -8) infect the skin and cause warts and sometimes non-
melanoma skin cancer. Mucosal types infect epithelial lining of anogenital tracts and oral
cavity. They are further divided to low-risk and high-risk types based on their propensity
to induce malignancies [62,63]. Low-risk HPVs (e.g. HPV-6 & -11) are associated only
with benign lesions such as genital warts and laryngeal papillomas. On the contrary,
high-risk HPVs (e.g. HPV-16 & -18) elicit various cancers including but not limited to
those in uterine cervix, vagina, anus, and oral cavity. Specifically, HPV-16 and -18 are
responsible for 60% and 20% of cervical cancer, respectively. Thus current prophylactic
vaccines commonly target these two major high-risk HPV types [64].
HPV virions are nonenveloped icosahedral particles that are 55 nm in diameter and
enclose 7.9 kb-long double-stranded DNA genome [62,63]. HPV encodes eight genes,
among which E5, E6, and E7 possess oncogenic activity. Two of these viral oncogenes,
E6 and E7, are invariably expressed in human cervical cancer, and their continued
expression is required for maintenance of the cancerous state. The strong tumorigenic
potential of high-risk HPVs stems, in part, from the ability of their E6 and E7
oncoproteins to inactivate the potent cellular tumor suppressor proteins p53 and pRb,
respectively.
Transgenic mice expressing high-risk HPV E6 and E7 individually or in combination
have been generated and extensively characterized for their cancer phenotypes. Although
these transgenic mice develop spontaneous skin tumors, they rarely develop cancers in
mucosal epithelia of anogenital tracts or in the oral cavity, indicating that HPV
oncogenes are not sufficient for promoting tumorigenesis in those relevant tissues.
Consistently, the majority of these mice succumb to cervical/vaginal cancer with
treatment with physiologic levels of exogenous estrogen [9], head & neck cancers with a
low dose of chemical carcinogen, 4-nitroquinoline 1-oxide (4-NQO) [65].
Cervical cancer develops slowly, is often established over a decade after initial infection
with high-risk HPVs, and only arises in those women whose infections do not resolve
spontaneously. Such persistent infections can lead to the development of severe cervical
intraepithelial neoplasia (CIN3) (Figure 1b) with a 3-year probability that varies from
approximately 14% for any high-risk HPVs (any) to 40% for HPV 16 [6]. Cytological
screening (i.e. the Pap smear) to detect CIN lesions in the cervix has greatly reduced cervical
cancer incidence in those countries with well-developed medical care systems. If not
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appropriately treated, however, CIN3 can progress to cervical cancer in at least 30% of
women, while in the rest, CIN3 lesions are thought to regress spontaneously [7]. The high
probability of spontaneous elimination of HPV infection and the relatively low frequency of
cervical cancer in women with persistent HPV infection pointed to the existence of non-viral
factors other than the virus that contribute to disease onset. A growing body of evidence
supports our hypothesis that estrogen is one such factor.
Estrogen synergizes with HPV oncogenes to cause cervical cancer in mice
The strongest evidence that estrogen contributes to cervical carcinogenesis comes from
laboratory studies on HPV transgenic mice. In these mice, multiple or individual HPV
oncogenes (i.e. E6 and E7) are placed under the transcriptional control of the human keratin
14 promoter, which directs their expression to stratified squamous epithelia including that of
the skin, oral cavity, anus, vagina and cervix. While these HPV transgenic mice can develop
spontaneous tumors, primarily in the skin, they rarely develop cervical cancers
spontaneously [8]. However, if HPV transgenic mice are treated with exogenous 17β-
estradiol, they efficiently develop cervical cancers [9–11]. Whereas HPV oncogenes have an
impact on normal cellular processes first at adolescent or adulthood when women are
infected by the virus for the first time, these transgenic mice start to express HPV oncogenes
from the early stages of embryonic development. In addition, whole epithelium in the cervix
is under the influence of HPV oncogenes when tumorigenic events are initiated, which is
different from the human situation where HPV oncogene expression is restricted to a limited
area of epithelium. Therefore, cancer initiation events and the cancer microenvironment in
these mouse models may be different from those in women. Nonetheless, these mice
recapitulated key aspects of cervical cancer in women in that (i) the progressive neoplastic
disease leading to frank cancer is highly similar to that observed in women; (ii) cancers
frequently arise in the transformation zone of the cervix where columnar epithelium
converts to squamous epithelium (Figure 1b); and (iii) cervical cancers arising in these mice
express similar biomarkers as found in human cervical cancer [12,13]. Only physiological
levels of estrogen sufficient to induce continuous estrus are necessary to efficiently promote
cervical carcinogenesis in HPV-transgenic mice [13]. These experimental conditions mimic
that seen in premenopausal women exposed to the continuous estrogenic stimulation such as
from oral contraceptives or as a consequence of pregnancy. In this mouse model, removal of
exogenous estrogen led to a diminishment in the progression of cervical disease and partial
regression of pre-existing neoplasia [14]. These mouse studies together provide compelling
evidence that estrogen contributes to cervical carcinogenesis.
Role of the estrogen receptor α in cervical carcinogenesis
Despite intrinsic caveats of most genetically modified mouse models including available
HPV transgenic mice [15], HPV transgenic mice have provided a powerful experimental
platform for dissecting the roles of viral and host genes in cervical cancer [16–20]. Given
the potency of estrogen in inducing cervical cancer in these mice, the roles of its nuclear
receptor ERα (ERβ was undetectable in the mouse cervix, as is the case in the human
cervix), was investigated [21]. In contrast to ERα-sufficient HPV transgenic mice, ERα-
deficient HPV transgenic mice failed to develop cervical cancer when treated with estrogen
(Figure 2a). In fact, estrogen-treated ERα-null HPV transgenic mice did not develop any
aspect of the progressive disease leading to cervical cancer, including the most cancer-prone
epithelium, atypical squamous metaplasia (ASM, Figure 1b). In addition, these mice failed
to display cervical hyperplasia, the normal acute response to estrogen stimulation. These
studies demonstrate an absolute requirement for ERα in mediating estrogen’s carcinogenic
properties in the cervix.
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Targeting ERα: a new mode of treating and/or preventing cervical cancer
Knowing that ERα is required for estrogen’s carcinogenic activities in the cervix [21] and
that estrogen contributes not only to the genesis but also to the maintenance of cervical
neoplastic disease [14], the utility of ERα antagonistic drugs in treating or preventing
cervical cancer was evaluated using this HPV transgenic mouse model. Two ERα
antagonists were evaluated, raloxifene and fulvestrant [22]. These are FDA-approved drugs
used in the treatment/prevention of human breast cancer, and are members of a class of
drugs referred to as selective estrogen receptor modulators (SERMs). Both raloxifene and
fulvestrant were highly effective in eliminating pre-existing cervical cancers with only a
month-long treatment period (Figure 2b). They also eliminated pre-existing CIN lesions,
which led to the hypothesis that ERα antagonists could also prevent cervical cancers from
arising. Indeed, treatment of CIN-bearing mice with fulvestrant during estrogen treatment
prevented CIN lesions from progressing to cancer [22]. Thus, in a preclinical model for
HPV-associated cervical cancer, inhibiting ERα function leads to the elimination and
prevention of cervical neoplastic disease, providing further evidence for the role of estrogen
and its receptor in cervical cancer. If this is translatable to human cervical cancer, SERMs
that inhibit ERα in the cervix will be effective in controlling this gynecological disease.
The interplay between estrogen and HPV
That there is such a strong synergy between estrogen and HPV oncogenes in the
development of cervical cancers in mice begs the question – what is responsible for the high
degree of interaction? Both estrogen and HPV E7 can independently induce cervical
epithelial hyperplasia [21]. In addition, estrogen and HPV oncoproteins regulate Eag1
potassium channel, of which inhibition leads to apoptosis of human cervical cancer cells
[23]. Chronic exposure to estrogen induces overexpression of Aurora-A, a centrosome
kinase, and centrosome amplification, leading to chromosomal instability in mammary gland
of ACI rats [24]. E6 and E7 each can inhibit cellular DNA damage responses, which in part
may contribute to their promoting genomic instability [25,26]. However, there is also data
indicating that estrogen and HPV affect each other’s activities. Estrogen and other ER
agonists have been shown by multiple investigators to induce the expression of HPV
oncogenes when they are under the control of the endogenous viral promoter [27–30]. This
could contribute to a synergy between estrogen and HPV in human cervical cancers, which
are ERα-positive. However, the mechanism by which estrogen increases HPV gene
expression remains unclear, as some of the studies demonstrating the effect of estrogen on
HPV gene expression were carried out using human cervical cancer cell lines that have lost
expression of ERα protein [27,28,30]. It is also important to note that this level of interplay
does not contribute to cervical carcinogenesis in the context of the above-described HPV
transgenic mice using K14 promoter-driven transgenes, as this promoter is not estrogen-
responsive [11]. However in a different HPV transgenic mouse model, in which the high-
risk HPV18 E6 and E7 oncogenes were kept under the control of the endogenous viral
promoter, estrogen induced expression of E6 and E7, and this correlated with increased
severity of cervical dysplasia [31]. Other hormone receptors, particularly glucocorticoid and
progesterone receptors, also have been implicated in modulating HPV gene expression by
activating the endogenous viral promoter and cooperating with high-risk HPV for cellular
transformation [32–34]. These observations support the hypothesis that cervical cancer
depends on estrogen. They also suggest that steroid hormones other than estrogen may be
implicated in cervical cancer.
In addition to estrogen having a potential effect on HPV gene expression and activity, the
converse may also be true. For example, HPV transcription factor E2 can cooperate with
nuclear receptor co-activators to increase the estrogen response element (ERE)-dependent
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transcriptional activity of ERα [35]. This could be relevant in the context of progressive
disease leading to the development of human cervical cancers. E2 is predicted to be
expressed in precancerous lesions, as well as in the subset of cervical cancers in which the
E2 gene is not disrupted by integration of the viral genome into the host genome. Both E6
and E7 have been argued also to enhance ERE-dependent activity [36], though other
investigators have claimed the opposite [37,38]. Contradictory results may stem from
differences in estrogen concentration and cell lines used in each study. This controversy can
be resolved with the use of HPV-negative normal cervical keratinocytes. Nonetheless, these
studies support a model for the role of estrogen and HPV in cervical cancer in which
estrogen and HPV have the capacity to influence each other’s activities (Figure 3).
Epidemiological data on the role of sex hormones in human cervical cancer
Although incidence for most epithelial cancers increase with age, estrogen-dependent
cancers do not share this age pattern [39]. Instead, after menopause they either increase
more slowly, or cease to increase, depending on the level of circulating and/or local
estrogens. Breast cancer is the best-studied example of estrogen-dependent epithelial cancer
[39,40], and knowledge gained from such studies has led to the vast use of SERMs in breast
cancer treatment [41], as well as the consideration of their use for breast cancer prevention
in high-risk women [42]. In unscreened populations, incidence rates of cervical cancer by
age behave in a way that closely resembles those of breast cancer, i.e. age-specific incidence
curves for cervical cancer in unscreened populations in Africa, Asia and Latin America
show a steep rise up to age 45 years and then a plateau [43]. In well-screened populations,
the age pattern of cervical cancer is different, i.e., incidence stops increasing at age 25-to-30
years when regularly scheduled cytological screening has been initiated and early detection
of precancerous cervical lesions reduces the risk of cervical cancer.
On account of the strong link between cervical cancer and HPV infection, which typically
first occurs soon after becoming sexually active, the age-related behavior of cervical cancer
may be driven by the natural history of HPV infections, i.e. the frequency of HPV infections
in a woman will correlate with the number of sexual partners she has at any given time in
life. A large bulk of epidemiological evidence suggests, however, that endogenous and
exogenous sex hormones also affect a woman’s risk of developing the disease, in
combination with HPV infection. In a collaborative re-analysis of over 16,000 women with
cervical cancer and twice as many cancer-free women from 25 different studies, it was
found that the number of full-term pregnancies (FTPs) and age at first FTP were associated
with cervical cancer risk after careful adjustment for lifetime number of sexual partners and
age at first FTP [44]. For example, Figure 4a shows that a woman who started bearing
children at age 17 years or younger and had seven FTPs or more had a relative risk (RR) of
3.3 of developing cervical cancer (95% confidence interval (CI): 2.7–4.0) compared to
nulliparous women. This trend was similar for squamous-cell carcinoma and
adenocarcinoma of the cervix [44]. Multiparity, however, showed no clear association with
CIN3/carcinoma in situ, whereas age at first FTP showed an inverse association that was
similar, but weaker than for cervical cancer. The increased risk of cervical cancer among
women with high parity has been hypothesized to be a consequence of alterations in female
hormones arising during pregnancy. Alternatively, immune suppression that is linked with
pregnancy could increase the risk of new HPV infections, and/or reduce the body’s ability to
eliminate pre-existing infections, thereby increasing the risk of neoplastic progression.
The use of combined oral contraceptives was also shown to increase cervical cancer risk
after careful adjustment for sexual and reproductive factors and screening history in the
aforementioned large collaborative reanalysis [45]. Among women still using oral
contraceptives, the risk of cervical cancer increased with increasing duration of use (RR for
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≥5 years of use versus never-users: 1.9; 95% CI: 1.7–2.1) (Figure 4b). The risk declined,
however, after this use ceased, and by 10 or more years had returned to that of never-users.
A similar pattern of risk was seen for squamous cell carcinoma and adenocarcinoma, and for
CIN3/carcinoma in situ. Among the relatively few users of progestogen-only injectable
contraceptives, the RRs found for cervical cancer were somewhat weaker, but not
incompatible, with the RRs found among oral contraceptive users [45]. These studies
provide further support that female hormones can increase risk of cervical cancer.
The relationship between events surrounding and following menopause (i.e. age at
menopause, use of hormone replacement therapy (HRT), and overweight/obesity, as the
strongest determinants of circulating estrogen levels in post-menopausal women) is still not
well understood. The International Collaboration of Epidemiological Studies of Cervical
Cancer has not reported pooled estimates of RRs for any of these potential risk factors, and
individual studies of cervical cancer do not show conclusive results. An association between
overweight/obesity and cervical cancer that is as strong as that for endometrial cancer, or
even breast cancer in post-menopausal women, can be excluded [46]. In a case-control study
from the United States, body mass index and waist-to-hip ratios were found to be directly
associated with risk of adenocarcinoma but not with squamous cell carcinoma of the cervix
[47]. Clearly further study is needed in this area of research.
Investigating the correlation between HRT and cervical cancer risk has been hampered to a
much greater extent than the assessment of hormonal contraceptives by two main problems:
i) the predominant use of HRT in rich countries where cervical cancer risk has been greatly
reduced by cytological screening; and ii) the additional tendency of HRT users to be
screened more intensively than non-users. The only relatively unbiased data on HRT and
cervical cancer and precancerous lesions derives, therefore, from the few randomized studies
of HRT. In the Women’s Health Initiative (WHI) trial, 15,733 women (aged 50–79 years)
with an intact uterus were randomized to receive either placebo or 0.625 mg/day of
conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate, with
cytological findings assessed during a 6-year follow-up period [48]. The annual incidence
rate of any cytological abnormality in the HRT group was significantly higher than in the
placebo group (hazard ratio: 1.4; 95% CI: 1.2–1.6) but no difference was found in incidence
rates of high-grade squamous intraepithelial lesions (HSIL, comparable to CIN2/CIN3) and
cervical cancer (found in only 54 and 10 women, respectively). A non-significantly higher
incidence of cytological abnormalities (hazard ratio: 1.4; 95% CI; 0.9–2.0) was also reported
among women in the HRT group in a smaller trial (2,561 randomized women, same
formulation as in the WHI trial) [49]. The excess was due to higher incidence of atypical
squamous cells of undetermined significance (hazard ratio: 1.6; 95% CI: 1.0–2.5) [49].
Randomized trials of HRT were clearly underpowered to estimate the difference in HSIL
and cervical cancer by hormone use, due to the extreme rarity of these conditions in the
well-screened middle-aged and elderly women included [48]. With respect to the excess of
mild cytological abnormalities in users, HRT has been reported to decrease the number of
false negative cytological results due to improved cellular maturation and less drying artifact
compared to untreated women of the same age [48].
A large prospective study on the use of SERMs in the prevention of breast cancer recurrence
is evaluating the effects of tamoxifen, a weak ERα agonist in the human cervix, and
raloxifene on breast cancer incidence and other disease outcomes, including other cancers
[50]. Unfortunately, it is unclear whether this study will shed light on the influence of
SERMs on risk of cervical cancer. First off, HPV infection and preexisting cervical lesions
were not evaluated. Second, as with HRT studies, the study population is primarily
postmenopausal (mean age 58.5, only 7% under 50 years of age) and from countries with
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screening programs that reduce the incidence of cervical cancer. Consequently the frequency
of cervical cancer is extremely low. There were no reported cases of cervical cancer in the
raloxifene treatment group (group size = 9745), and 1 case reported in the tamoxifen arm
(group size = 9726). Furthermore, there was no control arm (no drug) to this study.
Endogenous hormone levels can differ in women and, consequently, one group looked at
whether this can be a risk factor in cervical cancer. Levels of sex hormone-binding globulin,
estradiol, estone, estrone sulphate, dehydroepiandrosterone sulphate, and progesterone were
similar in 110 women, with CIN2/3 and cervical cancer, and 440 control women matched by
age and menopausal status [51]. The small study size and the reliance on a single measure of
hormone levels taken at the time of diagnosis were, however, important limitations of the
only study available on levels of endogenous hormones and cervical cancer [51].
To summarize the epidemiological studies, the plateau in cervical cancer incidence after age
45 years in unscreened populations and the increased risk among multiparous women and
long-term users of hormonal contraceptives are consistent with the hypothesis that female
hormones contribute to the risk of cervical cancer. Both FTPs and hormonal contraceptives
involve, however, exposure to high levels of both estrogen and progesterone. Lack of data
on the influence of age at menopause, different formulations of HRT and overweight/obesity
do not allow one to draw conclusions on which sex hormone(s) may be involved in
promoting cervical cancer in humans.
SERMs and cervical cancer
Because the cervix is highly responsive to estrogen, it has long been suspected that estrogen
may contribute to cervical cancer. Based on this, several clinical trials have been carried out
with tamoxifen that provided inconclusive results [52,53]. Unfortunately tomoxifen was a
poor choice of SERM to use as it acts as an ER agonist rather than ER antagonist in human
cervix and vagina [54]. Tamoxifen has also been evaluated for its effect on proliferation of
human cervical cancer cell lines; however, it is difficult to interpret these data because the
cells used are apparently ERα-negative, and tamoxifen had differential effects depending on
its concentration [28,55,56].
Indole-3-carbinol (I3C), a natural compound enriched in cruciferous vegetables, possesses
anti-estrogenic activity by modulating estrogen metabolism in a way that favors the
production of anti-estrogenic 2-hydroxyestrone [57]. It was also shown that I3C binds
weakly to ERα. Interestingly, this phytochemical and its metabolites have been shown to be
effective in preventing cervical disease in HPV transgenic mice [58,59] and increasing
regression of the disease in women [60]. It is, however, difficult to ascribe the anti-cervical
cancer activity of I3C to its anti-estrogenic function because of its multifunctional nature.
For instance, I3C prevents loss of PTEN in HPV transgenic mouse model and is efficient in
treating tumors that do not depend on estrogen [61].
Concluding Remarks
Several lines of evidence support a role for estrogen and ERα in human cervical cancer.
First, long-term use of oral contraceptives and/or multiple pregnancies increases the risk for
cervical cancer, and cervical cancer incidence plateaus after menopause. Second, estrogen
and ERα are required for cervical carcinogenesis, and SERMs are effective in controlling
cervical cancer in well-validated mouse models for HPV-associated cervical cancer. Third,
cervical cancer is often positive for ERα, although its functionality in such cancer has yet to
be demonstrated. Fourth, estrogen increases expression of E6 and E7 oncogenes, which are
the major driving force for cervical cancer. Further investigation of the role of estrogen and
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its receptors in human cervical cancer is indicated (Box 2). Such studies could lead to the
development of new effective therapies in the treatment or prevention of cervical cancer.
Box 2
Outstanding questions
Despite the long suspicion that estrogen may play a role in human cervical cancer, and
strong evidence that this is the case in mouse models for this cancer, the role of estrogen
and its receptors in human cervical cancer remains unclear. New research focusing on
this topic is needed. Critical to this area of research will be the availability of cell lines
derived from human cervical cancers in which the pattern of expression of estrogen
receptors reflects that seen in the cancers themselves. In the absence of ERα-positive cell
lines, alternative means (e.g. primary human cervical cancer xenografts) may have to be
employed.
From the clinical perspective, new therapies are most urgently needed for patients with
recurrent cervical cancer. Determining the dependence of these cancers on estrogen, and
their responsiveness to SERMs should be of utmost priority. The potential value of
SERMs in preventing cervical cancer in women with pre-existing CIN lesions is also
indicated from mouse model studies [22]. But because of SERMs’ unwanted side effects
such as induction of menopausal symptoms, particularly in premenopausal women, novel
drugs or delivery approaches may be needed to allow ERα antagonists to be useful in this
context.
Abbreviations
HPV human papillomavirus
HR high-risk
CIN cervical intraepithelial neoplasia
ASM atypical squamous metaplasia
RR relative risk
ER estrogen receptor
ERα estrogen receptor α
ERβ estrogen receptor β
GPR30 G protein-coupled estrogen receptor 1
FDA Federal Drug Administration
SERMs selective estrogen receptor modulators
ERE estrogen response element
FTP full-term pregnancies
CI confidence interval
HRT hormone replacement therapy
WHI Women’s Health Initiative
HSIL high-grade squamous intraepithelial lesion
PI3K phophatidyl inositol 3-kinase
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MAPK mitogen-activated protein kinase
FCIs floating confidence intervals
FSEs floating standard errors
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Figure 1.
Estrogen pathway and cervical carcinogenesis. (a) Estrogen pathway. Estrogen binds to its
cytosolic/nuclear receptors (ERα and ERβ) and membrane receptor GPR30 to exert its
functions. Estrogen binds to ERs in the cytoplasm and induces ER homo- or hetero-
dimerization. Estrogen-bound ERs then translocate to the nucleus, where they activate or
repress target genes by two different mechanisms: classical pathway: ER binds to ERE and
modulates target genes, and non-classical pathway: ER binds to AP1 or Sp1 transcription
factors associated with their recognition sites in enhancer elements and modifies their
function. Estrogen also binds to the membraneous receptor GPR30, a member of the G-
protein coupled receptor family, and rapidly transduces various signaling pathways
including but not limited to phosphatidyl inositol 3-kinase (PI3K), mitogen-activated protein
kinase (MAPK), and Ca2+ signaling (non-genomic pathway). (b) Progressive disease leading
to cervical cancer. It is believed that the multipotent reserve cells present in the
transformation zone of the cervix are the progenitor cell type for cervical cancer. High-risk
HPVs (HR-HPVs), such as HPV-16, infect and persist in these cells, and promote their
aberrant squamous differentiation, which leads to atypical squamous metaplasia (ASM).
ASM can progress to cervical intraepithelial neoplasia (CIN) grade 1–3 and eventually
cervical cancer. This progressive neoplastic disease process normally takes over a decade
following initial HPV infection before culminating in frank cancer. In most women, cervical
disease spontaneously resolves prior to the development of cervical cancer.
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Figure 2.
Requirement of ERα for genesis and persistence of cervical cancer. (a) Influence of ERα
status on cervical disease in HPV transgenic mice. Shown is the worst disease state in the
cervices of K14E7/ERα+/+ (red; +) or K14E7/ERα−/− (green; −) mice treated for 6 months
with 17β-estradiol. Note the complete absence of disease in mice deficient for ERα as
compared to the presence of high-grade dysplasia, CIN3 (33%), or cervical cancer (66%) in
ERα-sufficient mice. Data taken from [21]. (b) Effectiveness of SERMs in treating cervical
neoplasia in HPV transgenic mice. Shown is the worst disease state in the cervices of
K14E6E7 mice treated with 17β-estradiol for 6 months to induce cervical cancer, then either
left untreated (red; −) or treated with fulvestrant (green; F) or raloxifene (blue; R) for 1
month. Note the complete (100%) or near complete (92%) loss of disease in mice treated
with raloxifene or flulvestrant, respectively, compared to the retention of CIN3 (21%) or
cervical cancer (79%) in those mice not treated with a SERM. Data taken from [22].
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Figure 3.
Model for synergy between HPV and estrogen in cervical cancer. The three HPV oncogenes
E5, E6, and E7 contribute to varying degrees to the development of cervical cancer through
their abilities to induce cell proliferation, inhibit cell death, abrogate cellular DNA damage
responses, and induce genomic instability. Estrogen contributes to cervical cancer at least in
part through its ERα-dependent induction of cell proliferation. HPV gene products can either
enhance or suppress estrogen’s stimulation of ERα transcriptional activity. Estrogen can in
turn activate expression of HPV oncogenes potentially through ERα or perhaps other means.
The interplay between HPV and estrogen may contribute to the synergistic activities of these
viral and cellular factors in causing cervical cancer. Disrupting the estrogen/ERα pathway
provides a novel approach to preventing or treating cervical cancer, for example, through
SERMs.
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Figure 4.
Meta-analyses of risks of cervical cancer related to parity and oral contraceptive use. (a)
Relative risks (RRs) of cervical cancer and corresponding 95% floating confidence intervals
(FCIs) by number of full-term pregnancies (FTPs) stratified by age at first FTP [40]. Among
parous women, there was an increased risk of cervical cancer with number of FTPs within
each stratum of age at first FTP and vice versa. Compared to nulliparae, the risk for parity
increased across strata of younger age at first FTP. 1Conditioned on age and study or study
centre. 2As in1, and conditioned on age at first sexual intercourse and lifetime number of
sexual partners. (b) Relative risk (RR) of cervical cancer, floating standard errors (FSEs) and
corresponding floating confidence intervals (FCIs) in relation to time since last use within
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categories of duration of use of combined oral contraceptives [41]. For duration of use less
than 5 years, there was no significant increase of cervical cancer risk, compared to never
users, in any category of time since last use. For women who had used combined oral
contraceptives for 5 or more years, the RR in current use was almost twice that of never
users. By 10 or more years since last use, the risk was not significantly different from that in
never users. 1Conditioned on age and study centre. 2As in1, and conditioned on age at first
sexual intercourse, lifetime number of sexual partners, number of full-term pregnancies,
smoking and screening status.
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